Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Adaptive Biotechnologies reported a quarterly loss of $0.15 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.16, and an improvement from a loss of $0.22 per share a year ago, resulting in an earnings surprise of +6.25% [1] - The company achieved revenues of $93.97 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 38.15%, and showing significant growth from $46.44 million in the same quarter last year [2] - The stock has increased approximately 182.2% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] 分组2 - The earnings outlook for Adaptive Biotechnologies is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for the company was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Current consensus EPS estimate for the next quarter is -$0.15 on revenues of $67.16 million, and for the current fiscal year, it is -$0.68 on revenues of $245.1 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Adaptive Biotechnologies belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]